A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome

被引:0
作者
T. E. Woo
R. Lim
A. A. Heirali
N. Acosta
H. R. Rabin
C. H. Mody
R. Somayaji
M. G. Surette
C. D. Sibley
D. G. Storey
M. D. Parkins
机构
[1] University of Calgary,Department of Biological Sciences
[2] University of Calgary,Department of Medicine
[3] University of Calgary,Department of Microbiology, Immunology and Infectious Diseases
[4] McMaster University,Departments of Medicine, and Biochemistry and Biomedical Sciences
来源
Scientific Reports | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A diverse microbiota exists within the airways of individuals with non-cystic fibrosis bronchiectasis (nCFB). How the lung microbiome evolves over time, and whether changes within the microbiome correlate with future disease progression is not yet known. We assessed the microbial community structure of 133 serial sputa and subsequent disease course of 29 nCFB patients collected over a span of 4–16 years using 16S rRNA paired-end sequencing. Interestingly, no significant shifts in the microbial community of individuals were observed during extended follow-up suggesting the microbiome remains relatively stable over prolonged periods. Samples that were Pseudomonas aeruginosa culture positive displayed markedly different microbial community structures compared to those that were positive for Haemophilus influenzae. Importantly, patients with sputum of lower microbial community diversity were more likely to experience subsequent lung function decline as defined by annual change in ≥−1 FEV1% predicted. Shannon diversity values <1 were more prevalent in patients with FEV1 decline (P = 0.002). However, the relative abundance of particular core microbiota constituents did not associate with risk of decline. Here we present data confirming that the microbiome of nCFB individuals is generally stable, and that microbiome-based measurements may have a prognostic role as biomarkers for nCFB.
引用
收藏
相关论文
共 50 条
[21]   Update on non-cystic fibrosis bronchiectasis [J].
Bilton, Diana .
CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (06) :595-599
[22]   Management of non-cystic fibrosis bronchiectasis [J].
Webb, Philip ;
King, Jenny ;
Baxter, Caroline ;
Lord, Robert W. .
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (07)
[23]   Non-cystic fibrosis bronchiectasis in children [J].
Gursoy, Tugba Ramasli ;
Eyuboglu, Tugba Sismanlar ;
Aslan, Ayse Tana .
EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[24]   Effect of obstructive airway disease in patients with non-cystic fibrosis bronchiectasis [J].
Khalid, M ;
Saleemi, S ;
Zeitouni, M ;
Al Dammas, S ;
Khaliq, MR .
ANNALS OF SAUDI MEDICINE, 2004, 24 (04) :284-287
[25]   Statins for non-cystic fibrosis bronchiectasis [J].
Feldman, Charles .
LANCET RESPIRATORY MEDICINE, 2014, 2 (06) :431-432
[26]   Treatment of Non-Cystic Fibrosis Bronchiectasis [J].
Martinez Garcia, Miguel Angel ;
Maiz Carro, Luis ;
Catalan Serra, Pablo .
ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (12) :599-609
[27]   Cough in non-cystic fibrosis bronchiectasis [J].
Kantar, Ahmad ;
Song, Woo-Jung ;
Bush, Andrew ;
Chatziparasidis, Grigorios .
ERJ OPEN RESEARCH, 2024, 10 (06)
[28]   Non-cystic fibrosis bronchiectasis Response [J].
Murray, Maeve P. ;
Hill, Adam T. .
CLINICAL MEDICINE, 2009, 9 (04) :402-402
[29]   Management of Non-Cystic Fibrosis Bronchiectasis [J].
Dull, Stacey K. ;
Havlat, Brooke D. ;
Sanley, Michael J. ;
Malesker, Mark A. .
CONSULTANT PHARMACIST, 2018, 33 (11) :658-666
[30]   Exacerbations in non-cystic fibrosis bronchiectasis [J].
Sahnoun, Imen ;
Racil, Hajer ;
Hafaied, Safa ;
Bacha, Saoussen ;
Rouhou, Sana Cheikh ;
Chawech, Newel ;
Mhiri, Emna ;
Chabbou, Abdellatif .
EUROPEAN RESPIRATORY JOURNAL, 2014, 44